John R. Mascola
National Institutes of Health(US)Opexa Therapeutics (United States)(US)Flexion Therapeutics (United States)(US)OPKO Health (United States)(US)Institut de Recherche Vaccinale(FR)National Institute of Health of Thailand(TH)National Institute of Allergy and Infectious Diseases(US)Laboratoire d'Excellence Canaux Ioniques d'Intérêt Thérapeutique(FR)Celldex Therapeutics (United States)(US)ApeX Therapeutics (United States)(US)
Publications by Year
Research Areas
HIV Research and Treatment, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research, HIV/AIDS drug development and treatment, T-cell and B-cell Immunology
Most-Cited Works
- → An mRNA Vaccine against SARS-CoV-2 — Preliminary Report(2020)3,453 cited
- → Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1(2010)1,763 cited
- → SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness(2020)1,618 cited
- → Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies(2000)1,243 cited
- → Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01(2010)1,158 cited
- → Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates(2020)1,152 cited